TY - JOUR
T1 - Mood homeostasis, low mood, and history of depression in 2 large population samples
AU - Taquet, Maxime
AU - Quoidbach, J.
AU - Gross, James J.
AU - Saunders, Kate E.A.
AU - Goodwin, Guy M.
N1 - Funding Information:
reported receiving grants from the Royal College of Psychiatrists and the Foulkes Foundation during the conduct of the study. Dr Saunders reported receiving grant BRC-1215-20005 from the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre during the conduct of the study. Dr Goodwin reported receiving personal fees from Allergan, Inc, Angelini Pharma, COMPASS Pathways, Merck & Co, Johnson & Johnson, Lundbeck, Inc, Medscape, Minerva Neurosciences, Inc, P1vital, Pfizer, Inc, Sage Therapeutics, Inc, Servier Laboratories, Shire Plc, and Sun Pharmaceutical Industries, Inc, outside the submitted work and holding an equity stake in P1vital and P1vital products. No other disclosures were reported.
Funding Information:
Funding/Support: This study was supported by fellowships with financial support from the Foulkes Foundation and the Royal College of Psychiatrists (Dr Taquet) and grant RYC-2016-21020 from the Ministerio de Economía, Industria y Competitividad, Gobierno de España (Dr Quoidbach).
Publisher Copyright:
© 2020 American Medical Association. All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Importance: Existing therapeutic options are insufficient to tackle the disease burden of depression, and new treatments are sorely needed. Defining new psychotherapeutic targets is challenging given the paucity of coherent mechanistic explanations for depression. Objective: To assess whether mood homeostasis (ie, the stabilization of one's mood by engaging in mood-modifying activities) is a possible new therapeutic target by testing the hypothesis that people with low (vs high) mean mood and people with (vs without) a history of depression have impaired mood homeostasis. Design, Setting, and Participants: The quantitative association between mood and daily activities was computed in 2 large case-control studies based on the 58sec data set (collected from December 1, 2012, to May 31, 2014, and analyzed from April 1 to 30, 2019), and the World Health Organization Study on Global Aging and Adult Health (WHO SAGE) data set (collected from January 1, 2007, to December 31, 2010, and analyzed from June 1 to 30, 2019). The 58sec data set consists of self-enrolled participants from high-income countries. The WHO SAGE data set consists of nationally representative participants in low- and middle-income countries recruited via cluster sampling. Main Outcomes and Measures: The main outcome (defined before data analysis) was the difference in mood homeostasis between people with high vs low mean mood (58sec data) and between people with vs without a history of depression (WHO SAGE data). Results: A total of 28212 participants from the 58sec data set (65.8% female; mean [SD] age, 28.1 [9.0] years) and 30116 from the WHO SAGE data set (57.0% female; mean [SD] age, 57.8 [14.7] years) were included, for an overall study population of 58 328 participants. Mood homeostasis was significantly lower in people with low (vs high) mean mood (0.63 [95% CI, 0.45 to 0.79] vs 0.96 [95% CI, 0.96 to 0.98]; P <.001) and in people with (vs without) a history of depression (0.03 [95% CI, -0.26 to 0.24] vs 0.68 [95% CI, 0.55 to 0.75]; P <.001). In dynamic simulations, lower mood homeostasis led to more depressive episodes (11.8% vs 3.8% yearly risk; P <.001) that lasted longer (4.19 vs 2.90 weeks; P =.006). Conclusions and Relevance: In this study, mood homeostasis appeared to have been impaired in people with low mood and in those with a history of depression. Mood homeostasis may therefore provide new insights to guide the development of treatments for depression..
AB - Importance: Existing therapeutic options are insufficient to tackle the disease burden of depression, and new treatments are sorely needed. Defining new psychotherapeutic targets is challenging given the paucity of coherent mechanistic explanations for depression. Objective: To assess whether mood homeostasis (ie, the stabilization of one's mood by engaging in mood-modifying activities) is a possible new therapeutic target by testing the hypothesis that people with low (vs high) mean mood and people with (vs without) a history of depression have impaired mood homeostasis. Design, Setting, and Participants: The quantitative association between mood and daily activities was computed in 2 large case-control studies based on the 58sec data set (collected from December 1, 2012, to May 31, 2014, and analyzed from April 1 to 30, 2019), and the World Health Organization Study on Global Aging and Adult Health (WHO SAGE) data set (collected from January 1, 2007, to December 31, 2010, and analyzed from June 1 to 30, 2019). The 58sec data set consists of self-enrolled participants from high-income countries. The WHO SAGE data set consists of nationally representative participants in low- and middle-income countries recruited via cluster sampling. Main Outcomes and Measures: The main outcome (defined before data analysis) was the difference in mood homeostasis between people with high vs low mean mood (58sec data) and between people with vs without a history of depression (WHO SAGE data). Results: A total of 28212 participants from the 58sec data set (65.8% female; mean [SD] age, 28.1 [9.0] years) and 30116 from the WHO SAGE data set (57.0% female; mean [SD] age, 57.8 [14.7] years) were included, for an overall study population of 58 328 participants. Mood homeostasis was significantly lower in people with low (vs high) mean mood (0.63 [95% CI, 0.45 to 0.79] vs 0.96 [95% CI, 0.96 to 0.98]; P <.001) and in people with (vs without) a history of depression (0.03 [95% CI, -0.26 to 0.24] vs 0.68 [95% CI, 0.55 to 0.75]; P <.001). In dynamic simulations, lower mood homeostasis led to more depressive episodes (11.8% vs 3.8% yearly risk; P <.001) that lasted longer (4.19 vs 2.90 weeks; P =.006). Conclusions and Relevance: In this study, mood homeostasis appeared to have been impaired in people with low mood and in those with a history of depression. Mood homeostasis may therefore provide new insights to guide the development of treatments for depression..
UR - http://www.scopus.com/inward/record.url?scp=85083879003&partnerID=8YFLogxK
U2 - 10.1001/jamapsychiatry.2020.0588
DO - 10.1001/jamapsychiatry.2020.0588
M3 - Article
C2 - 32320005
AN - SCOPUS:85083879003
SN - 2168-622X
VL - 77
SP - 944
EP - 951
JO - JAMA Psychiatry
JF - JAMA Psychiatry
IS - 9
ER -